Cargando…

Calcitonin Gene-Related Peptide Monoclonal Antibodies Versus Botulinum Neurotoxin a in the Preventive Treatment of Chronic Migraine: An Adjusted Indirect Treatment Comparison Meta-Analysis

Purpose: Calcitonin gene-related peptide monoclonal antibodies (CGRPmAbs) are new agents approved by the US Food and Drug Administration for preventive treatment of chronic migraine. Comparison between CGRPmAbs and previously approved Botulinum neurotoxin A (BoNT-A) will inform optimal preventive tr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yao-Yao, Ye, Xiao-Qian, Tang, Tai-Chun, She, Tian-Wei, Chen, Min, Zheng, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170150/ https://www.ncbi.nlm.nih.gov/pubmed/34093199 http://dx.doi.org/10.3389/fphar.2021.671845

Ejemplares similares

Calcitonin Gene–Related Peptide Monoclonal Antibody Versus Botulinum Toxin for the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment Comparison
por: Lu, Jiajie, et al.
Publicado: (2021)

New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
por: Scuteri, Damiana, et al.
Publicado: (2019)

Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
por: Wang, Xing, et al.
Publicado: (2021)

Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins
por: Schaefer, Sara M., et al.
Publicado: (2015)

Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine
por: Xu, Fang, et al.
Publicado: (2019)

Development and Characterization of Monoclonal Antibodies to Botulinum Neurotoxin Type E
por: Bever, Candace S., et al.
Publicado: (2019)

Tyrosine Phosphorylation of Botulinum Neurotoxin Protease Domains
por: Toth, Stephen, et al.
Publicado: (2012)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Monoclonal Antibodies that Inhibit the Proteolytic Activity of Botulinum Neurotoxin Serotype/B
por: Fan, Yongfeng, et al.
Publicado: (2015)

Monoclonal Antibodies Against the Calcitonin Gene-Related Peptide and Its Receptor in Japanese Adolescents With Migraines
por: Katsuki, Masahito, et al.
Publicado: (2023)

Calcitonin gene-related peptide (receptor) antibodies: an exciting avenue for migraine treatment
por: MaassenVanDenBrink, Antoinette, et al.
Publicado: (2018)

Botulinum neurotoxin type A for the treatment of pain: not just in migraine and trigeminal neuralgia
por: Sandrini, Giorgio, et al.
Publicado: (2017)

A Cell Line for Detection of Botulinum Neurotoxin Type B
por: Rust, Aleksander, et al.
Publicado: (2017)

Sheep Monoclonal Antibodies Prevent Systemic Effects of Botulinum Neurotoxin A1
por: Mukherjee, Jean, et al.
Publicado: (2012)

Use of Monoclonal Antibodies in the Sensitive Detection and Neutralization of Botulinum Neurotoxin Serotype B
por: Cheng, Luisa W., et al.
Publicado: (2015)

Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B
por: Matsumura, Takuhiro, et al.
Publicado: (2020)

Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale
por: Cohen, Fred, et al.
Publicado: (2022)

Commentary: A Cell Line for Detection of Botulinum Neurotoxin Type B
por: Pickett, Andy
Publicado: (2018)

Calcitonin gene-related peptide antagonists versus botulinum toxin A for the preventive treatment of chronic migraine protocol of a systematic review and network meta-analysis: A protocol for systematic review
por: She, Tianwei, et al.
Publicado: (2020)

Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines
por: Siddiqui, Mariah, et al.
Publicado: (2021)

Neutralization of Botulinum Neurotoxin by a Human Monoclonal Antibody Specific for the Catalytic Light Chain
por: Adekar, Sharad P., et al.
Publicado: (2008)

Botulinum Neurotoxin for the Treatment of Neuropathic Pain
por: Egeo, Gabriella, et al.
Publicado: (2020)

Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
por: Deng, Hong, et al.
Publicado: (2020)

Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine
por: Pederson, Susan, et al.
Publicado: (2021)

The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
por: Hou, Min, et al.
Publicado: (2017)

The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis
por: Fernández-Bravo-Rodrigo, Jaime, et al.
Publicado: (2022)

Treatment Patterns for Calcitonin Gene-Related Peptide Monoclonal Antibodies Including Galcanezumab versus Conventional Preventive Treatments for Migraine: A Retrospective US Claims Study
por: Varnado, Oralee J, et al.
Publicado: (2022)

Correction: Comparing the Efficacy, Safety, and Superiority of Calcitonin Gene-Related Peptide Monoclonal Antibodies and Botox in Preventing and Treating Migraines
por: Siddiqui, Mariah, et al.
Publicado: (2021)

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data
por: Pavelic, Antun R., et al.
Publicado: (2022)

Efficacy and Safety of Anti-calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies in Preventing Migraines: A Systematic Review
por: Muddam, Meghana Reddy, et al.
Publicado: (2023)

Eluxadoline Versus Antispasmodics in the Treatment of Irritable Bowel Syndrome: An Adjusted Indirect Treatment Comparison Meta-analysis
por: Qin, Di, et al.
Publicado: (2022)

Monoclonal Antibodies Targeting the Alpha-Exosite of Botulinum Neurotoxin Serotype/A Inhibit Catalytic Activity
por: Fan, Yongfeng, et al.
Publicado: (2015)

Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H
por: Fan, Yongfeng, et al.
Publicado: (2016)

A Highly Specific Monoclonal Antibody for Botulinum Neurotoxin Type A-Cleaved SNAP25
por: Rhéaume, Catherine, et al.
Publicado: (2015)

Safety and Pharmacokinetics of a Four Monoclonal Antibody Combination against Botulinum C and D Neurotoxins
por: Snow, Doris M., et al.
Publicado: (2019)

Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention
por: Garg, Shuchita, et al.
Publicado: (2020)

Clinical and Neurophysiological Effects of Botulinum Neurotoxin Type A in Chronic Migraine
por: Valente, Mariarosaria, et al.
Publicado: (2021)

Botulinum Neurotoxins (BoNTs)—Antibody and Vaccine
por: Lou, Jianlong, et al.
Publicado: (2018)

Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice
por: Kang, Won-Ho, et al.
Publicado: (2022)

European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention
por: Sacco, Simona, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ckpis5lr72enntaoondgihvatu